Royal Bank of Canada Trims Biogen (NASDAQ:BIIB) Target Price to $269.00
Biogen (NASDAQ:BIIB – Free Report) had its price objective cut by Royal Bank of Canada from $292.00 to $269.00 in a report released on Friday, Benzinga reports. They currently have an outperform rating on the biotechnology company’s stock. Several other research analysts have also issued reports on the stock. Robert W. Baird lowered their price […]
7 Oct 07:51 · The Markets Daily